The purpose of the study is to determine in patients currently being administered
antipsychotic pharmacotherapy whether PEAR-004 can further reduce symptoms of schizophrenia
as measured by the Positive and Negative Syndrome Scale (PANSS).
The overall rationale for the study is to assess the first prescription digital therapeutic
(PDT) in schizophrenia using a form of proven psychosocial intervention, cognitive behavioral
therapy (CBT), to supplement standard of care with antipsychotic medications.